KCA 1K followers (April 2021)KCA 4:3, article 3, fig 2KCA 4:2, article 6, fig 1KCA 3:2, article 5, figure2KCA 3:1, article 2, figure 1KCA 3:1, article 1, figure 1Fourth-Line Therapy in Metastatic Renal Cell Carcinoma (2:1)Perioperative Systemic Therapy for Metastatic Renal Cell CarcinomaRationale to prime the immune systemNew KCA issue

We reached the 1K milestone on Twitter in April 2021. Thanks to all our followers! Thanks also to our social media editor Neeraj Agarwal for all the great work engaging the research community & spreading word about the new content published in our Kidney Cancer journal! Follow us at: @KCA_Journal

Review article that looks to validate the association of rs307826 in VEGFR3 to first-line sunitinib outcome in an independent cohort of m-ccRCC patients. From: Beuselinck, et al., Kidney Cancer, Vol.4, Iss.3, pp. 139-149, 2020

Renal cell carcinoma with inferior vena cava extension. A modified thrombus classification was proposed with visuals of successive levels defined, in part, as shown in the visual. From: Leibovich, et al., Kidney Cancer, Vol.4, Iss.2, pp. 111-115, 2020

This research article examines the role microRNAs (miRNAS) in the progression of cancer types, including clear cell renal cell carcinoma (ccRCC). L: Prognostic miRNAs (pink) and master regulator (blue) of the prognostic genes. R: Identified 96 miR-22 target genes. From: Gong, et al., KCA 3:2, pp. 119-132, 2019

This review examines cell-free circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma. Visual illustrates circulating cell-free DNA (cfDNA) and ctDNA found in serum and plasma fractions from blood. From: Hahn, et al., Kidney Cancer, Vol.3, Iss.1, pp. 7-13, 2019

This review examines radiation therapy in the treatment of renal cell carcinoma with an aim to expand the discussion on treatment options. Visual is an example of a patient treated with stereotactic ablative radiotherapy for a renal tumor. From: Choi and Yu, Kidney Cancer, Vol.3, Iss.1, pp. 1-6, 2019

This study indicates that 4LT appears to have activity in mRCC patients. The figure shows total number of patients receiving the therapies (A); with (B) indicating therapies given to patients who received 4LT. From: Stukalin, et al., Kidney Cancer, Vol.2, Iss.1, pp. 31–36, 2018.

Renal cell carcinoma's disease biology: inactivated VHL gene leads to overexpression of HIF. Genes activated by HIF transcript growth factors such as VEGF, PDGF and FGF. From: Maia et al., Kidney Cancer, Vol.1, Iss.1, pp. 15-29, 2017

Rationale to prime the immune system with PD-1 blockade prior to nephrectomy. From: Harshman et al., Kidney Cancer, Vol.1, Iss.1, pp. 31-40, 2017

Following on from the launch Kidney Cancer in summer 2017, we are now pleased to announce publication the latest issue of the journal. Click on the banner image to go straight to the issue!

Welcome to Kidney Cancer

Editorial Board

Primo Nery Lara

Primo N. Lara Jr, MD

University of California Davis Comprehensive Cancer Center
Sacramento, CA, USA

Email: kca@iospress.com

Peter Mulder

Peter Mulders, MD, PhD

Radboud UMC Nijmegen,The Netherlands

Email: kca@iospress.com


Submission Guidelines




Authors are requested to submit their manuscript electronically to the online submission system msTracker. Note that the manuscript should be uploaded as one file with tables and figures included.


No front page content has been created yet.